Market news

Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.

ORLANDO, FL / ACCESS Newswire / August 7, 2026 / RedChip Companies will air interviews with Virax Biolabs Group Ltd. (Nasdaq:VRAX) and Transcode Therapeutics Inc. (Nasdaq:RNAZ) on the RedChip Small Stocks, Big Money™ show, a sponsored television program ...

Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies, today published a shareholder update from Chief Executive Officer James Foster providing context on the Company's fiscal 2026 Annual Report and subsequent commercial, financing and Nasdaq compliance developments.

The collaboration initially focuses on tuberculosis research in Thailand, where Fosun has identified customer interest.

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $

Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose

Virax Biolabs Signs Multi-Country Supply PartnershipVirax Biolabs Group Limited (NASDAQ:VRAX) shares surged 100% on Thursday after the company announced an exclusive commercial supply agreement with Fosun Diagnostics for its ImmuneSelect immune profiling product portfolio. The agreement covers six Southeast Asian markets—Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia—and establishes a framework for immediate product shipments through purchase orders, creating new near-term

Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock

Virax stock soars on a commercial supply agreement with Fosun Diagnostics. But disciplined investors are cautioned against chasing the momentum in VRAX shares.

Virax Biolabs Group Limited (NASDAQ:VRAX) stock is up during Thursday’s premarket session, as the company has signed a multi-country commercial supply agreement with Fosun Diagnostics for its ImmuneSelect product line, which is aimed at immune profiling. The agreement opens access to multiple Southeast Asian markets, potentially driving significant revenue growth for the company as it expands its commercial footprint. Virax Biolabs is developing in vitro diagnostic technologies for viral and imm